<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01870375</url>
  </required_header>
  <id_info>
    <org_study_id>0905M65804</org_study_id>
    <secondary_id>U54NS065768</secondary_id>
    <secondary_id>0905M65804</secondary_id>
    <nct_id>NCT01870375</nct_id>
  </id_info>
  <brief_title>Longitudinal Studies of Brain Structure and Function in MPS Disorders</brief_title>
  <official_title>Longitudinal Studies of Brain Structure and Function in MPS Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lysosomal Disease Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neurobehavioral function and quality of life are compromised in many patients with
      mucopolysaccharidosis (MPS) disorders. The long-term goals of this research are to: 1) more
      accurately inform patients/parents regarding potential neurobehavioral outcomes; 2) develop
      sensitive measures of disease progression and central nervous system (CNS) treatment outcome;
      and 3) help clinical researchers develop direct treatments for specific brain
      structures/functions. The investigators hypothesize that specific and localized neuroimaging
      and neuropsychological findings and their relationship will be distinct for each MPS
      disorder. It is further hypothesized that without treatment, functions will decline and
      structure will change over time in a predictable fashion, and will be related to locus of
      abnormality and stage of disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mucopolysaccharidoses (MPS diseases) are lysosomal disorders (inborn errors of
      metabolism) that progressively affect most organ systems in the body, usually beginning in
      childhood. Recent treatment advances have produced amelioration of some of these
      malfunctions, but notably brain and bone have been difficult to effectively treat. This
      research addresses the brain abnormalities in the MPS disorders, about which little is known.

      The objectives of this research are:

        1. to identify abnormalities of central nervous system (CNS) structure and function as well
           as to measure quality-of-life (QOL) in both treated and untreated MPS patients over
           time. The investigators will accomplish this through longitudinal studies of enrolled
           patients in designated centers in North America.

        2. to develop quantitative measurements of change, including direct measurement of
           neuropsychological function; surrogate MRI markers; and biomarkers to measure stage of
           disease and treatment outcomes.

        3. to examine the degree to which independent variables have an impact on both functional
           and structural outcome. Independent variables may include, but are not limited to: age
           at first treatment, severity of disease, types of medical abnormalities, nature of
           genetic mutation, medical events, and sensory abnormalities.

        4. to examine how treatments such as Enzyme Replacement Therapy (ERT), Hematopoietic Cell
           Transplant (HCT), substrate reduction, and other palliative and rehabilitative therapies
           differentially affect CNS structure and function, as well as the subject's quality of
           life.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cognitive Ability (IQ)</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
    <description>Age-appropriate IQ tests will be administered at baseline and during subject's annual visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
    <description>Age-appropriate Quality of Life measures will be administered at baseline and during subject's annual visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuropsychological Status</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
    <description>Memory, Attention, Visual Spatial, and Visual Motor functions will be assessed with age-appropriate measures administered at baseline and during subject's annual visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Emotional and Behavioral Health</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
    <description>Age-appropriate measures of emotional and behavioral health will be administered at baseline and during subject's annual visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Shown in Magnetic Resonance Imaging of the Brain</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
    <description>Magnetic resonance imaging of each subject's brain will be performed at baseline and during subject's annual visit to acquire volumetric, diffusion tensor imaging (DTI), and resting state data. These data will be analyzed to identify any changes occurring over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Adaptive Functions</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
    <description>Vineland Adaptive Behavior Scales, a measure of communication, daily living skills, socialization and motor function, will be administered at baseline and during subject's annual visit.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mucopolysaccharidosis Type I</condition>
  <condition>Mucopolysaccharidosis Type II</condition>
  <condition>Mucopolysaccharidosis Type VI</condition>
  <condition>Mucopolysaccharidosis Type IV</condition>
  <condition>Mucopolysaccharidosis Type VII</condition>
  <arm_group>
    <arm_group_label>MPS IH, MPS IHS, MPS IS</arm_group_label>
    <description>MPS IH (Hurler syndrome) patients; MPS IHS (Hurler-Scheie syndrome) patients; and MPS IS (Scheie syndrome) patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MPS II</arm_group_label>
    <description>Hunter syndrome patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MPS IV</arm_group_label>
    <description>Morquio syndrome patients who will be considered for enrollment in the study on an individual basis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MPS VI</arm_group_label>
    <description>Maroteaux-Lamy syndrome patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MPS VII</arm_group_label>
    <description>Sly syndrome patients who will be considered for enrollment in the study on an individual basis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have a verified diagnosis of MPS I, II, IV, VI or VII, aged 6-25 years.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any MPS I, II, IV, VI or VII child or adult aged 6-25 years

        Exclusion Criteria:

          -  Exclusion Criteria for Neuroimaging:

               -  Participants with:

                    -  Pacemakers

                    -  Any indwelling electronic device including programmable shunts

                    -  Orthodontic braces unless they are not made of metal

                    -  Other implanted metal in the body other than titanium

                    -  Unable to stay still during MRI because of low cognitive function,
                       behavioral dysregulation, or young age, if the patient is not a clinical
                       patient having sedation/anesthesia

                    -  Pregnancy

          -  Exclusion Criteria for Neuropsychological and Neurobehavioral Testing

               -  Participants who:

                    -  Are too functionally impaired for testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chester B. Whitley, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ashley Schneider</last_name>
    <role>Study Director</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Harmatz, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Oakland Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michal Inbar-Feigenberg, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital for Sick Children, Toronto, Ontario, CA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heather Lau, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>New York University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley Schneider</last_name>
    <phone>612-301-1371</phone>
    <email>amwiesen@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oakland Children's Hospital</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo Ann Johnson</last_name>
      <phone>510-428-3885</phone>
      <phone_ext>5421</phone_ext>
      <email>JAJohnson@mail.cho.org</email>
    </contact>
    <investigator>
      <last_name>Paul Harmatz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Ford</last_name>
      <phone>212-263-6981</phone>
      <email>michele.ford@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Heather Lau, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nirosha Srimathan</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>202639</phone_ext>
      <email>nirosha.srimathan@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Michal Inbar-Feigenberg, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://rarediseasesnetwork.epi.usf.edu/</url>
    <description>The National Institutes of Health's Rare Diseases Clinical Research Network</description>
  </link>
  <link>
    <url>http://www.rarediseasesnetwork.org/LDN/index.htm</url>
    <description>Lysosomal Disease Network's page at Rare Diseases Clinical Research Network site</description>
  </link>
  <link>
    <url>http://www.lysosomaldiseasenetwork.org/</url>
    <description>Lysosomal Disease Network's own site</description>
  </link>
  <link>
    <url>http://mpssociety.org/</url>
    <description>National MPS Society (in the United States)</description>
  </link>
  <reference>
    <citation>Aldenhoven M, Wynn RF, Orchard PJ, O'Meara A, Veys P, Fischer A, Valayannopoulos V, Neven B, Rovelli A, Prasad VK, Tolar J, Allewelt H, Jones SA, Parini R, Renard M, Bordon V, Wulffraat NM, de Koning TJ, Shapiro EG, Kurtzberg J, Boelens JJ. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015 Mar 26;125(13):2164-72. doi: 10.1182/blood-2014-11-608075. Epub 2015 Jan 26.</citation>
    <PMID>25624320</PMID>
  </reference>
  <reference>
    <citation>Braunlin E, Orchard PJ, Whitley CB, Schroeder L, Reed RC, Manivel JC. Unexpected coronary artery findings in mucopolysaccharidosis. Report of four cases and literature review. Cardiovasc Pathol. 2014 May-Jun;23(3):145-51. doi: 10.1016/j.carpath.2014.01.001. Epub 2014 Jan 10. Review.</citation>
    <PMID>24508139</PMID>
  </reference>
  <reference>
    <citation>Stevenson DA, Rudser K, Kunin-Batson A, Fung EB, Viskochil D, Shapiro E, Orchard PJ, Whitley CB, Polgreen LE. Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI. J Pediatr Rehabil Med. 2014;7(2):159-65. doi: 10.3233/PRM-140285.</citation>
    <PMID>25096868</PMID>
  </reference>
  <reference>
    <citation>Polgreen LE, Thomas W, Orchard PJ, Whitley CB, Miller BS. Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1-2 years in children with Hurler or Hunter syndrome. Mol Genet Metab. 2014 Feb;111(2):101-6. doi: 10.1016/j.ymgme.2013.11.013. Epub 2013 Dec 11.</citation>
    <PMID>24368158</PMID>
  </reference>
  <reference>
    <citation>Taylor NE, Dengel DR, Lund TC, Rudser KD, Orchard PJ, Steinberger J, Whitley CB, Polgreen LE. Isokinetic muscle strength differences in patients with mucopolysaccharidosis I, II, and VI. J Pediatr Rehabil Med. 2014;7(4):353-60. doi: 10.3233/PRM-140305.</citation>
    <PMID>25547887</PMID>
  </reference>
  <reference>
    <citation>Wolf DA, Banerjee S, Hackett PB, Whitley CB, McIvor RS, Low WC. Gene therapy for neurologic manifestations of mucopolysaccharidoses. Expert Opin Drug Deliv. 2015 Feb;12(2):283-96. doi: 10.1517/17425247.2015.966682. Epub 2014 Dec 16. Review.</citation>
    <PMID>25510418</PMID>
  </reference>
  <reference>
    <citation>Ou L, Herzog TL, Wilmot CM, Whitley CB. Standardization of α-L-iduronidase enzyme assay with Michaelis-Menten kinetics. Mol Genet Metab. 2014 Feb;111(2):113-5. doi: 10.1016/j.ymgme.2013.11.009. Epub 2013 Nov 26.</citation>
    <PMID>24332804</PMID>
  </reference>
  <reference>
    <citation>Kunin-Batson AS, Shapiro EG, Rudser KD, Lavery CA, Bjoraker KJ, Jones SA, Wynn RF, Vellodi A, Tolar J, Orchard PJ, Wraith JE. Long-Term Cognitive and Functional Outcomes in Children with Mucopolysaccharidosis (MPS)-IH (Hurler Syndrome) Treated with Hematopoietic Cell Transplantation. JIMD Rep. 2016;29:95-102. Epub 2016 Jan 30.</citation>
    <PMID>26825088</PMID>
  </reference>
  <reference>
    <citation>Polgreen LE, Kunin-Batson A, Rudser K, Vehe RK, Utz JJ, Whitley CB, Dickson P. Pilot study of the safety and effect of adalimumab on pain, physical function, and musculoskeletal disease in mucopolysaccharidosis types I and II. Mol Genet Metab Rep. 2017 Jan 15;10:75-80. doi: 10.1016/j.ymgmr.2017.01.002. eCollection 2017 Mar.</citation>
    <PMID>28119823</PMID>
  </reference>
  <results_reference>
    <citation>Shapiro E, Guler OE, Rudser K, Delaney K, Bjoraker K, Whitley C, Tolar J, Orchard P, Provenzale J, Thomas KM. An exploratory study of brain function and structure in mucopolysaccharidosis type I: long term observations following hematopoietic cell transplantation (HCT). Mol Genet Metab. 2012 Sep;107(1-2):116-21. doi: 10.1016/j.ymgme.2012.07.016. Epub 2012 Jul 20.</citation>
    <PMID>22867884</PMID>
  </results_reference>
  <results_reference>
    <citation>Eisengart JB, Rudser KD, Tolar J, Orchard PJ, Kivisto T, Ziegler RS, Whitley CB, Shapiro EG. Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome. J Pediatr. 2013 Feb;162(2):375-80.e1. doi: 10.1016/j.jpeds.2012.07.052. Epub 2012 Sep 10.</citation>
    <PMID>22974573</PMID>
  </results_reference>
  <results_reference>
    <citation>Shapiro EG, Nestrasil I, Rudser K, Delaney K, Kovac V, Ahmed A, Yund B, Orchard PJ, Eisengart J, Niklason GR, Raiman J, Mamak E, Cowan MJ, Bailey-Olson M, Harmatz P, Shankar SP, Cagle S, Ali N, Steiner RD, Wozniak J, Lim KO, Whitley CB. Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment. Mol Genet Metab. 2015 Sep-Oct;116(1-2):61-8. doi: 10.1016/j.ymgme.2015.06.002. Epub 2015 Jun 17.</citation>
    <PMID>26095521</PMID>
  </results_reference>
  <results_reference>
    <citation>Yund B, Rudser K, Ahmed A, Kovac V, Nestrasil I, Raiman J, Mamak E, Harmatz P, Steiner R, Lau H, Vekaria P, Wozniak JR, Lim KO, Delaney K, Whitley C, Shapiro EG. Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II. Mol Genet Metab. 2015 Feb;114(2):170-7. doi: 10.1016/j.ymgme.2014.12.299. Epub 2014 Dec 9.</citation>
    <PMID>25541100</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahmed A, Whitley CB, Cooksley R, Rudser K, Cagle S, Ali N, Delaney K, Yund B, Shapiro E. Neurocognitive and neuropsychiatric phenotypes associated with the mutation L238Q of the α-L-iduronidase gene in Hurler-Scheie syndrome. Mol Genet Metab. 2014 Feb;111(2):123-7. doi: 10.1016/j.ymgme.2013.11.014. Epub 2013 Dec 12.</citation>
    <PMID>24368159</PMID>
  </results_reference>
  <results_reference>
    <citation>Shapiro EG, Rudser K, Ahmed A, Steiner RD, Delaney KA, Yund B, King K, Kunin-Batson A, Eisengart J, Whitley CB. A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II. Mol Genet Metab Rep. 2016 Apr 1;7:32-9. doi: 10.1016/j.ymgmr.2016.03.005. eCollection 2016 Jun.</citation>
    <PMID>27114914</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahmed A, Shapiro E, Rudser K, Kunin-Batson A, King K, Whitley CB. Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI. Mol Genet Metab Rep. 2016 Apr 1;7:27-31. doi: 10.1016/j.ymgmr.2016.03.006. eCollection 2016 Jun.</citation>
    <PMID>27114913</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahmed A, Rudser K, Kunin-Batson A, Delaney K, Whitley C, Shapiro E. Mucopolysaccharidosis (MPS) Physical Symptom Score: Development, Reliability, and Validity. JIMD Rep. 2016;26:61-8. doi: 10.1007/8904_2015_485. Epub 2015 Aug 25.</citation>
    <PMID>26303610</PMID>
  </results_reference>
  <results_reference>
    <citation>Polgreen LE, Vehe RK, Rudser K, Kunin-Batson A, Utz JJ, Dickson P, Shapiro E, Whitley CB. Elevated TNF-α is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI. Mol Genet Metab. 2016 Apr;117(4):427-30. doi: 10.1016/j.ymgme.2016.01.012. Epub 2016 Jan 28.</citation>
    <PMID>26873528</PMID>
  </results_reference>
  <results_reference>
    <citation>Eisengart JB, Jarnes J, Ahmed A, Nestrasil I, Ziegler R, Delaney K, Shapiro E, Whitley C. Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome. Mol Genet Metab Rep. 2017 Sep 27;13:64-68. doi: 10.1016/j.ymgmr.2017.07.012. eCollection 2017 Dec.</citation>
    <PMID>28983455</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2011</study_first_submitted>
  <study_first_submitted_qc>June 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mucopolysaccharidosis</keyword>
  <keyword>Longitudinal</keyword>
  <keyword>Brain</keyword>
  <keyword>Cognition</keyword>
  <keyword>Quality-of-Life</keyword>
  <keyword>Hurler syndrome</keyword>
  <keyword>Hunter syndrome</keyword>
  <keyword>Hurler-Scheie syndrome</keyword>
  <keyword>Scheie syndrome</keyword>
  <keyword>Maroteaux-Lamy syndrome</keyword>
  <keyword>MPS I</keyword>
  <keyword>MPS II</keyword>
  <keyword>MPS VI</keyword>
  <keyword>Mucopolysaccharidosis type I</keyword>
  <keyword>Mucopolysaccharidosis type II</keyword>
  <keyword>Mucopolysaccharidosis type VI</keyword>
  <keyword>MPS IV</keyword>
  <keyword>MPS VII</keyword>
  <keyword>Mucopolysaccharidosis type IV</keyword>
  <keyword>Mucopolysaccharidosis type VII</keyword>
  <keyword>Morquio syndrome</keyword>
  <keyword>Sly syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidosis VI</mesh_term>
    <mesh_term>Mucopolysaccharidosis IV</mesh_term>
    <mesh_term>Osteochondrodysplasias</mesh_term>
    <mesh_term>Mucopolysaccharidosis VII</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study's data will be input to the Data Management and Coordinating Center (&quot;DMCC&quot;), which is a part of the NIH-funded Rare Diseases Clinical Research Network. Eventually the data will be available to researchers on the database of Genotypes and Phenotypes (&quot;dbGaP&quot;), a part of National Center for Biotechnology Information, U.S. National Library of Medicine.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

